Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024:2842:103-127.
doi: 10.1007/978-1-0716-4051-7_5.

Reader-Effectors as Actuators of Epigenome Editing

Seong Hu Kim  1 , Karmella A Haynes  2
Affiliations

Reader-Effectors as Actuators of Epigenome Editing

Seong Hu Kim et al. Methods Mol Biol. 2024.

Abstract

Epigenome editing applications are gaining broader use for targeted transcriptional control as more enzymes with diverse chromatin-modifying functions are being incorporated into fusion proteins. Development of these fusion proteins, called epigenome editors, has outpaced the study of proteins that interact with edited chromatin. One type of protein that acts downstream of chromatin editing is the reader-effector, which bridges epigenetic marks with biological effects like gene regulation. As the name suggests, a reader-effector protein is generally composed of a reader domain and an effector domain. Reader domains directly bind epigenetic marks, while effector domains often recruit protein complexes that mediate transcription, chromatin remodeling, and DNA repair. In this chapter, we discuss the role of reader-effectors in driving the outputs of epigenome editing and highlight instances where abnormal and context-specific reader-effectors might impair the effects of epigenome editing. Lastly, we discuss how engineered reader-effectors may complement the epigenome editing toolbox to achieve robust and reliable gene regulation.

Keywords: DNA methylation; Histone posttranslational modification; Reader-effector; Transcription.

PubMed Disclaimer

References

    1. Nakamura M, Gao Y, Dominguez AA, Qi LS (2021) CRISPR technologies for precise epigenome editing. Nat Cell Biol 23:11–22. https://doi.org/10.1038/s41556-020-00620-7 - DOI - PubMed
    1. Li J, Mahata B, Escobar M et al (2021) Programmable human histone phosphorylation and gene activation using a CRISPR/Cas9-based chromatin kinase. Nat Commun 12:896. https://doi.org/10.1038/s41467-021-21188-2 - DOI - PubMed - PMC
    1. Franklin KA, Shields CE, Haynes KA (2022) Beyond the marks: reader-effectors as drivers of epigenetics and chromatin engineering. Trends Biochem Sci 47:417–432. https://doi.org/10.1016/j.tibs.2022.03.002 - DOI - PubMed - PMC
    1. Stepper P, Kungulovski G, Jurkowska RZ et al (2016) Efficient targeted DNA methylation with chimeric dCas9–Dnmt3a–Dnmt3L methyltransferase. Nucleic Acids Res 45:1703–1713. https://doi.org/10.1093/nar/gkw1112 - DOI - PMC
    1. Günther K, Rust M, Leers J et al (2013) Differential roles for MBD2 and MBD3 at methylated CpG islands, active promoters and binding to exon sequences. Nucleic Acids Res 41:3010–3021. https://doi.org/10.1093/nar/gkt035 - DOI - PubMed - PMC

LinkOut - more resources